These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 7948280)

  • 1. Erythropoietin treatment in peritoneal dialysis patients.
    Nissenson AR
    Perit Dial Int; 1994; 14 Suppl 3():S63-9. PubMed ID: 7948280
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Erythropoietin in continuous ambulatory peritoneal dialysis: experience with subcutaneous administration.
    Eisele G; Bailie GR; Clement C; Wong E
    Perit Dial Int; 1992; 12(1):34-6. PubMed ID: 1543777
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In patients treated with peritoneal dialysis, icodextrin improves erythropoietin-resistant anemia through blockade of asialo receptors on hepatocytes.
    Adachi Y; Nakagawa Y; Nishio A
    Adv Perit Dial; 2006; 22():41-4. PubMed ID: 16983937
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recombinant human erythropoietin dosage in children undergoing hemodialysis and continuous ambulatory peritoneal dialysis.
    Sieniawska M; Roszkowska-Blaim M
    Pediatr Nephrol; 1997 Oct; 11(5):628-30. PubMed ID: 9323294
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The pharmacokinetics of intraperitoneal erythropoietin administered undiluted or diluted in dialysate.
    Bargman JM; Jones JE; Petro JM
    Perit Dial Int; 1992; 12(4):369-72. PubMed ID: 1420495
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
    Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
    Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Erythropoietin use in peritoneal dialysis patients.
    Zimmerman SW; Johnson CA
    Am J Kidney Dis; 1991 Oct; 18(4 Suppl 1):38-41. PubMed ID: 1928078
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multicenter trial of erythropoietin in patients on peritoneal dialysis.
    Nissenson AR; Korbet S; Faber M; Burkart J; Gentile D; Hamburger R; Mattern W; Schreiber M; Swartz R; Van Stone J
    J Am Soc Nephrol; 1995 Jan; 5(7):1517-29. PubMed ID: 7703390
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Erythropoietin and peritoneal dialysis: the efficacy of intraperitoneal dosing.
    Nissenson AR
    Perit Dial Int; 1992; 12(4):350-2. PubMed ID: 1420491
    [No Abstract]   [Full Text] [Related]  

  • 10. Subcutaneous recombinant human erythropoietin in children with renal anemia on continuous ambulatory peritoneal dialysis.
    Aufricht C; Balzar E; Steger H; Lothaller MA; Frenzel K; Kohlhauser C; Kiss H; Khoss AE; Kernova T
    Acta Paediatr; 1993 Nov; 82(11):959-62. PubMed ID: 8111178
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effects of recombinant human erythropoietin on functional health and well-being in chronic dialysis patients.
    Beusterien KM; Nissenson AR; Port FK; Kelly M; Steinwald B; Ware JE
    J Am Soc Nephrol; 1996 May; 7(5):763-73. PubMed ID: 8738812
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factors related to erythropoietin hypo-responsiveness in patients on chronic peritoneal dialysis.
    Wei M; Bargman JM; Oreopoulos DG
    Int Urol Nephrol; 2007; 39(3):935-40. PubMed ID: 17534732
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of once- versus thrice-weekly subcutaneous recombinant human erythropoietin in children receiving continuous cycling peritoneal dialysis.
    Ongkingco JR; Ruley EJ; Turner ME; Fragale MR
    Am J Nephrol; 1994; 14(1):14-8. PubMed ID: 8017476
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Erythropoietin requirements: a comparative multicenter study between peritoneal dialysis and hemodialysis.
    Coronel F; Herrero JA; Montenegro J; Fernandez C; Gandara A; Conesa J; Rivera MT; Torrente J; Portolés J; Gomez-Martino JR
    J Nephrol; 2003; 16(5):697-702. PubMed ID: 14733416
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Statement on the clinical use of recombinant erythropoietin in anemia of end-stage renal disease. Ad Hoc Committee for the National Kidney Foundation.
    Am J Kidney Dis; 1989 Sep; 14(3):163-9. PubMed ID: 2672796
    [No Abstract]   [Full Text] [Related]  

  • 16. Erythropoietin overview--1993.
    Nissenson AR
    Blood Purif; 1994; 12(1):6-13. PubMed ID: 7986477
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Erythropoietin-beta in the treatment of anemia in patients with chronic renal insufficiency].
    Dimković N
    Med Pregl; 2001; 54(5-6):235-40. PubMed ID: 11759218
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of subcutaneous recombinant human erythropoietin in children undergoing continuous cycling peritoneal dialysis.
    Sinai-Trieman L; Salusky IB; Fine RN
    J Pediatr; 1989 Apr; 114(4 Pt 1):550-4. PubMed ID: 2926567
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Androgens potentiate the effects of erythropoietin in the treatment of anemia of end-stage renal disease.
    Ballal SH; Domoto DT; Polack DC; Marciulonis P; Martin KJ
    Am J Kidney Dis; 1991 Jan; 17(1):29-33. PubMed ID: 1986567
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of recombinant human erythropoietin (EPO) to correct the anemia of end-stage renal disease: a progress report.
    Adamson W; Egrie JC; Browne JK; Downing MR; Eschbach W
    Behring Inst Mitt; 1988 Aug; (83):188-92. PubMed ID: 3071336
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.